Introduce Daratumumab/Hyaluronid in Subcu, Perc, New Tech 8

This code describes the administration of Daratumumab and Hyaluronidase-fihj, a combination drug, directly into the subcutaneous tissue. This is a percutaneous procedure, meaning it involves puncturing the skin with a needle to deliver the medication. The "New Technology Group 8" designation indicates it's a recently approved or innovative therapeutic approach.

This code is used when a patient receives a subcutaneous injection of Daratumumab and Hyaluronidase-fihj for the treatment of specific hematologic malignancies, such as multiple myeloma or light chain amyloidosis. It applies to the therapeutic administration of this particular combination product.

• Verify that both Daratumumab and Hyaluronidase-fihj were administered as a combined product.
• Confirm the administration route was subcutaneous and performed percutaneously.
• Ensure the documentation supports the use of this specific new technology agent.